COMPOSITION
Each capsule contains:
Iptacopan …………….…… 200 mg
INDICATION
LuciPta is a complement Factor B inhibitor indicated for the treatment of:
- Paroxysmal Nocturnal Hemoglobinuria (PNH): Treatment of adults with PNH.
- Immunoglobulin A Nephropathy (IgAN): To reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally with a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
- Complement 3 Glomerulopathy (C3G): Treatment of adults with C3G to reduce proteinuria.
The IgAN indication is approved under accelerated approval based on the reduction of proteinuria. Continued approval may depend on confirmation of clinical benefit.
DOSAGE AND USE
The recommended dosage of LuciPta is 200 mg orally twice daily, with or without food.
Swallow capsules whole. Do not open, break, or chew the capsules.
If a dose is missed, take it as soon as possible and resume the regular dosing schedule.
PNH patients switching from anti-C5 therapies:
- For patients switching from eculizumab, initiate LuciPta no later than one week after the last dose of eculizumab.
- For patients switching from ravulizumab, initiate LuciPta no later than six weeks after the last dose of ravulizumab.
DOSAGE FORMS AND STRENGTHS
Capsules: 200 mg.
STORAGE
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F to 86°F).
Keep medicine out of the reach of Children.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS (LAO) CO., LTD
No. 26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION
To be sold by retail on prescription of a Registered physician only, and as directed by the physician. Keep medicine out of reach of Children. Do not administer LuciPta during Pregnancy and Lactation.
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/lucipta-iptacopan-200mg/
Related News
-
LuciTala Side Effects — Blood Count Changes and Clinical Trial Safety
Introduction Cancer medicines can affect patients in different ways. Some side effects…
2026-11-06
-
LuciTala Dosage and Administration — How to Take Talazoparib Safely
Introduction Taking an oral cancer medicine at home can be convenient, but…
2026-11-04
-
LuciTala (Talazoparib): How PARP Inhibition Works in Certain Cancers
Introduction A cancer diagnosis often brings difficult questions about treatment, expected outcomes…
2026-11-02
-
LuciNav Side Effects — Hyperglycaemia, Risks and Patient Monitoring
Introduction Targeted cancer medicines are designed to act on particular biological pathways,…
2026-10-31
-
How to Take LuciNav Safely — Dosage, Monitoring and Precautions
Introduction Taking an oral cancer medicine involves more than following a daily…
2026-10-26
-
LuciNav (Inavolisib) for PIK3CA-Mutated Breast Cancer
Introduction A breast cancer diagnosis can bring uncertainty, particularly when the disease…
2026-10-21



